Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-l-phenylalanine in CCS-bearing animal models

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10B (45–74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500 mg BPA/kg).